Stock listing
NASDAQ:MNOV MediciNova, Inc. Stock
Home listing (NASDAQ) of MediciNova, Inc.
Follow MediciNova, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:MNOV
$1.31 USD -0.02 (-1.5%)
Close on Nov 20, 2026
- Day range
- $1.27 – $1.31 USDNov 20, 2026
- Volume
- 48,972 sharesNov 20, 2026
- Market cap
- $67.11M USDAt the close on Nov 20, 2026 · price × 51.23M shares outstanding
- 52-week range
- $1.22 – $3.90 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $900,525 USDMedian day 69,900 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:MNOV · Home | $1.31 USD | -0.02 (-1.5%) | 48,972 | $1.27 | $1.31 | $1.27 | $1.33 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MNOV · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $1.31 | -0.02 | -1.5% | $1.27 | $1.31 | $1.27 | 48,972 | |
| $1.33 | -0.01 | -0.7% | $1.32 | $1.41 | $1.26 | 115,567 | |
| $1.34 | 0.00 | 0.0% | $1.375 | $1.39 | $1.32 | 57,887 | |
| $1.34 | -0.055 | -3.9% | $1.381 | $1.41 | $1.34 | 95,443 | |
| $1.395 | -0.005 | -0.4% | $1.40 | $1.445 | $1.39 | 61,649 | |
| $1.40 | -0.01 | -0.7% | $1.40 | $1.42 | $1.40 | 12,072 | |
| $1.41 | +0.01 | +0.7% | $1.43 | $1.43 | $1.40 | 18,854 | |
| $1.40 | -0.07 | -4.8% | $1.548 | $1.548 | $1.40 | 65,001 | |
| $1.47 | +0.01 | +0.7% | $1.46 | $1.47 | $1.421 | 54,523 | |
| $1.46 | +0.01 | +0.7% | $1.47 | $1.48 | $1.44 | 14,229 | |
| $1.45 | 0.00 | 0.0% | $1.45 | $1.47 | $1.45 | 139,459 | |
| $1.45 | +0.03 | +2.1% | $1.44 | $1.538 | $1.43 | 50,037 | |
| $1.42 | -0.02 | -1.4% | $1.43 | $1.49 | $1.41 | 56,684 | |
| $1.44 | +0.04 | +2.9% | $1.40 | $1.53 | $1.40 | 47,866 | |
| $1.40 | 0.00 | 0.0% | $1.42 | $1.42 | $1.38 | 29,658 | |
| $1.40 | -0.07 | -4.8% | $1.46 | $1.50 | $1.39 | 52,996 | |
| $1.47 | +0.06 | +4.3% | $1.42 | $1.49 | $1.401 | 25,005 | |
| $1.41 | +0.01 | +0.7% | $1.42 | $1.42 | $1.39 | 37,749 | |
| $1.40 | +0.01 | +0.7% | $1.42 | $1.47 | $1.40 | 89,906 | |
| $1.39 | -0.02 | -1.4% | $1.40 | $1.42 | $1.39 | 25,300 | |
| $1.41 | 0.00 | 0.0% | $1.41 | $1.42 | $1.38 | 30,500 | |
| $1.41 | +0.05 | +3.7% | $1.37 | $1.41 | $1.37 | 31,500 | |
| $1.36 | -0.04 | -2.9% | $1.40 | $1.44 | $1.36 | 37,100 | |
| $1.40 | -0.02 | -1.4% | $1.40 | $1.45 | $1.37 | 144,200 | |
| $1.42 | -0.03 | -2.1% | $1.47 | $1.50 | $1.42 | 80,200 | |
| $1.45 | -0.02 | -1.4% | $1.47 | $1.53 | $1.45 | 58,800 | |
| $1.47 | -0.03 | -2.0% | $1.51 | $1.55 | $1.46 | 96,200 | |
| $1.50 | -0.04 | -2.6% | $1.56 | $1.56 | $1.50 | 34,800 | |
| $1.54 | +0.02 | +1.3% | $1.49 | $1.58 | $1.48 | 127,800 | |
| $1.52 | -0.02 | -1.3% | $1.54 | $1.57 | $1.52 | 69,900 | |
| $1.54 | -0.07 | -4.3% | $1.60 | $1.61 | $1.53 | 109,400 | |
| $1.61 | -0.04 | -2.4% | $1.65 | $1.68 | $1.60 | 78,000 | |
| $1.65 | -0.11 | -6.3% | $1.72 | $1.72 | $1.65 | 120,000 | |
| $1.76 | -0.02 | -1.1% | $1.87 | $1.89 | $1.74 | 212,900 | |
| $1.78 | +0.15 | +9.2% | $1.67 | $1.84 | $1.67 | 274,500 | |
| $1.63 | -0.05 | -3.0% | $1.69 | $1.72 | $1.63 | 263,200 | |
| $1.68 | -0.24 | -12.5% | $1.86 | $1.86 | $1.66 | 369,800 | |
| $1.92 | -0.18 | -8.6% | $2.05 | $2.07 | $1.77 | 595,100 | |
| $2.10 | -0.48 | -18.6% | $2.40 | $2.45 | $1.69 | 1,617,500 | |
| $2.58 | -0.07 | -2.6% | $2.68 | $2.69 | $2.53 | 251,900 | |
| $2.65 | -0.15 | -5.4% | $2.67 | $2.67 | $2.48 | 452,800 | |
| $2.80 | -0.10 | -3.4% | $2.90 | $3.02 | $2.75 | 395,800 | |
| $2.90 | -0.40 | -12.1% | $3.16 | $3.30 | $2.90 | 2,474,200 | |
| $3.30 | -0.02 | -0.6% | $3.28 | $3.40 | $3.03 | 666,900 | |
| $3.32 | -0.13 | -3.8% | $3.20 | $3.62 | $2.72 | 1,634,400 | |
| $3.45 | +0.93 | +36.9% | $2.84 | $3.90 | $2.83 | 7,413,200 | |
| $2.52 | +0.50 | +24.8% | $2.16 | $2.62 | $2.15 | 1,420,800 | |
| $2.02 | +0.15 | +8.0% | $1.94 | $2.07 | $1.93 | 207,100 | |
| $1.87 | +0.06 | +3.3% | $1.91 | $1.92 | $1.87 | 68,500 | |
| $1.81 | +0.07 | +4.0% | $1.73 | $1.84 | $1.73 | 45,900 | |
| $1.74 | -0.05 | -2.8% | $1.78 | $1.78 | $1.72 | 67,800 | |
| $1.79 | +0.04 | +2.3% | $1.82 | $1.85 | $1.75 | 106,200 | |
| $1.75 | +0.12 | +7.4% | $1.67 | $1.76 | $1.65 | 137,800 | |
| $1.63 | +0.01 | +0.6% | $1.62 | $1.63 | $1.55 | 96,700 | |
| $1.62 | +0.19 | +13.3% | $1.45 | $1.63 | $1.45 | 111,300 | |
| $1.43 | -0.01 | -0.7% | $1.44 | $1.46 | $1.43 | 14,300 | |
| $1.44 | 0.00 | 0.0% | $1.46 | $1.46 | $1.42 | 20,000 | |
| $1.44 | 0.00 | 0.0% | $1.43 | $1.46 | $1.43 | 18,700 | |
| $1.44 | +0.02 | +1.4% | $1.42 | $1.45 | $1.42 | 16,900 | |
| $1.42 | -0.06 | -4.1% | $1.49 | $1.52 | $1.42 | 25,400 | |
| $1.48 | -0.09 | -5.7% | $1.57 | $1.58 | $1.43 | 40,700 | |
| $1.57 | +0.04 | +2.6% | $1.55 | $1.58 | $1.48 | 87,127 | |
| $1.53 | +0.14 | +10.1% | $1.39 | $1.54 | $1.39 | 118,900 | |
| $1.39 | +0.02 | +1.5% | $1.38 | $1.40 | $1.37 | 26,000 | |
| $1.37 | -0.01 | -0.7% | $1.38 | $1.38 | $1.33 | 24,400 |
Splits
1 split · NASDAQ:MNOV · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- NASDAQ:MNOV
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 12, 2026
MediciNova CEO Provides Shareholder Update
Latest deck · Nov 13, 2026
Q3 2026 Earnings Presentation
Earnings · 20 slides
Latest news
MediciNova CEO Provides Shareholder Update
Oct 12, 2026
Closed $1.54 (+1.3%) on Oct 12, 2026
MediciNova to Participate in the Maxim Growth Summit
Oct 6, 2026
Closed $1.65 (-6.3%) on Oct 6, 2026
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
Sep 29, 2026
Closed $1.92 (-8.6%) on Sep 29, 2026
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
Sep 24, 2026
Closed $2.65 (-5.4%) on Sep 24, 2026
MediciNova to Participate in Two Investor Conferences in September
Sep 8, 2026
Closed $1.75 (+7.4%) on Sep 8, 2026
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
Jul 15, 2026
Closed $1.40 (+2.2%) on Jul 15, 2026
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
Jun 8, 2026
Closed $1.30 (-0.8%) on Jun 8, 2026
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
May 26, 2026
Closed $1.33 (-2.9%) on May 27, 2026
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
Apr 27, 2026
Closed $1.36 (-0.7%) on Apr 28, 2026
MediciNova to Participate at the 38th Annual ROTH Conference
Mar 16, 2026
Closed $1.45 (+7.4%) on Mar 16, 2026
MediciNova, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 144 in all · newest Oct 12, 2026 · oldest 2019
- Decks
- 33 decks · latest Nov 13, 2026
Where MediciNova, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:MNOV · Home listing · This page | NASDAQ | United States | USD |
| Tokyo:4875 メディシノバ・インク | Tokyo | Japan | JPY |
| BOATS:MNOV | BOATS | United States | USD |
Valuation
EV/sales 41.1× against a median of 12.4×: 4th lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $38.45M USD
- P/E
- Loss
- EV/sales
- 41.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.6×
- Gross margin
- 46.8%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.56
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| MediciNova, Inc. · NASDAQ:MNOV | US$67.11M | US$38.45M | n/a | 41.1× | n/a | 1.6× | n/a | 0.0× | 0.56 |
| MAIA Biotechnology, Inc. · AMEX:MAIA | US$68.54M | US$68.54M | n/a | n/a | n/a | 4.7× | n/a | 0.0× | 1.62 |
| ABIONYX Pharma SA · EURONEXT:ABNX | US$68.36M | US$55.53M | n/a | 12.4× | n/a | 4.0× | −136.6% | 1.0× | n/a |
| Cingulate Inc. · NASDAQ:CING | US$67.48M | US$1.21B | n/a | n/a | n/a | 3.3× | n/a | 56.0× | 1.41 |
| Energenesis Biomedical Co., Ltd. · TWSE:6657 | US$67.22M | US$47.02M | n/a | 203× | n/a | 3.1× | n/a | 0.0× | n/a |
| Dicot Pharma AB · OMXSTO:DICOT | US$66.56M | US$44.51M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | n/a |
| Cardiff Oncology, Inc. · NASDAQ:CRDF | US$66.34M | US$32.82M | n/a | 58.7× | n/a | 2.4× | n/a | 0.0× | 1.32 |
| Polaryx Therapeutics, Inc. · NASDAQ:PLYX | US$66.30M | US$57.86M | n/a | n/a | n/a | 8.7× | n/a | 0.0× | 1.66 |
| PMV Pharmaceuticals, Inc. · NASDAQ:PMVP | US$66.17M | −US$36.25M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.43 |
| Gossamer Bio, Inc. · NASDAQ:GOSS | US$65.57M | US$55.23M | n/a | 0.7× | n/a | n/a | −159.5% | n/a | 1.56 |
| Tenaya Therapeutics, Inc. · NASDAQ:TNYA | US$65.32M | US$1.38M | n/a | 0.5× | n/a | 1.2× | n/a | 0.1× | 2.42 |
| Median of the others | US$66.45M | US$51.12M | 12.4× | 3.1× | −148.0% | 0.0× | 1.56 |
Forecasts
3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 8.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.26 · 3 analysts
- Revenue, year to Dec 2026
- 730K · 3 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Yuichi Iwaki | Executive Chairman of the Board, President and Chief Executive Officer, Founder |
| Kazuko Matsuda | Member of the Board of Directors, Senior Vice President, Chief Medical Officer, Representative, Tokyo Office |
Board
| Director | Role |
|---|---|
| Yuichi Iwaki | Executive Chairman of the Board, President and Chief Executive Officer, Founder |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · After close | −0.4% |
| Q2 2026 | Aug 13, 2026 · After close | 0.0% |
| Q1 2026 | May 14, 2026 · After close | −1.4% |
| Q4 2025 | Feb 20, 2026 · Before open | −3.2% |
| Q3 2025 | Nov 12, 2025 · After close | −1.9% |
| Q2 2025 | Aug 14, 2025 · After close | +0.8% |
| Q1 2025 | May 13, 2025 · After close | −6.2% |
| Q4 2024 | Feb 19, 2025 · After close | −9.9% |
| Q3 2024 | Nov 13, 2024 · After close | −8.8% |
| Q2 2024 | Aug 8, 2024 · After close | +0.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · After close | +4.8% |
| Q4 2023 | Feb 15, 2024 · After close | +0.7% |
| Q3 2023 | Nov 9, 2023 · After close | −0.6% |
| Q2 2023 | Aug 9, 2023 · After close | +1.7% |
| Q1 2023 | May 11, 2023 · After close | 0.0% |
| Q4 2022 | Feb 16, 2023 · After close | +2.6% |
| Q3 2022 | Nov 10, 2022 · After close | −0.9% |
| Q2 2022 | Aug 11, 2022 · After close | +2.0% |
| Q1 2022 | May 12, 2022 · After close | +1.7% |
| Q4 2021 | Feb 16, 2022 · After close | −3.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 20 slides | Nov 13, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 31 slides | Sep 11, 2026 |
| Investor Presentation (May 2026) | Investor deck | 25 slides | May 2026 |
| Investor Presentation (March 2025) | Investor deck | 17 slides | March 2025 |
| International Symposium on ALS/MND 2018 | Conference | 35 slides | December 2018 |
| Technical Presentation (2018) | Technical | 18 slides | 2018 |
| International Symposium on ALS/MND 2017 | Conference | 44 slides | 2017 |
| Technical Presentation (2017) | Technical | 20 slides | 2017 |
| Investor Presentation (November 2016) | Investor deck | 36 slides | Nov 10, 2016 |
| Investor Presentation (September 2015) | Investor deck | 21 slides | Sep 25, 2015 |
All 33 decks
Financings
| Raise | Date |
|---|---|
| Common stock Announced: raise Buyers: YAII PN, Ltd (Yorkville Advisors Global LP) (Committed to buy up to $30 million worth of common stock over 36 months at 97% of the market price, at the Company's discretion) Use of proceeds: To further advance R&D programs and for general corporate activities | Jul 31, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$3.88 a share on Jan 31, 2005.
- Price
- US$3.88 a share
- Shares offered
- 30,000,000 shares of common stock
- Offering size
- US$116.4 million
- Underwriter
- Daiwa Securities SMBC
- Shares delivered
- On or about Feb 7, 2005
Steps
| Step | When |
|---|---|
| Filed publicly | Oct 1, 2004 |
| Amended 4 times | Newest Jan 27, 2005 |
| Final prospectus, with the price | Jan 31, 2005 |
Filings
| Filing | Filed |
|---|---|
| 424B1 · Prospectus | Jan 31, 2005 |
| S-1/A · Registration statement, amended | Jan 27, 2005 |
| 8-A12G · Registration of a class of shares | Jan 26, 2005 |
| CORRESP · Letter to the SEC | Jan 25, 2005 |
| S-1/A · Registration statement, amended | Jan 25, 2005 |
| S-1/A · Registration statement, amended | Jan 6, 2005 |
| UPLOAD · Letter from the SEC | Dec 14, 2004 |
| S-1/A · Registration statement, amended | Nov 24, 2004 |
| UPLOAD · Letter from the SEC | Oct 28, 2004 |
| S-1 · Registration statement | Oct 1, 2004 |
Open IPO · From the cover of the final prospectus (424B1) filed Jan 31, 2005
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 409.7K | 0 | 1.00M | 0 | 4.04M | 4.00M | 0 | 0 | 0 | 0 |
| Cost of revenue | 378.6K | 21.1K | 20.3K | 212.4K | 21.3K | 23.9K | 25.9K | 28.1K | 14.1K | |
| Gross profit | 31.1K | -21.1K | 1.00M | -212.4K | 4.04M | -21.3K | -23.9K | -25.9K | -28.1K | -14.1K |
| Research and development | 6.70M | 6.80M | 5.30M | 8.70M | 8.10M | 7.10M | 5.70M | 5.30M | 3.90M | 3.10M |
| Selling, general and administrative | 5.95M | 5.22M | 4.98M | 5.24M | 5.49M | 6.45M | 7.95M | 9.96M | 8.80M | 7.36M |
| Operating income | -13.3M | -12.7M | -9.90M | -14.6M | -10.2M | -14.2M | -14.0M | -15.6M | -13.0M | -10.9M |
| Depreciation and amortization | 20.1K | 21.1K | 20.3K | 17.7K | 26.1K | 21.3K | 23.9K | 25.9K | 28.1K | 14.1K |
| EBITDA | -13.3M | -12.7M | -9.88M | -14.6M | -10.2M | -14.2M | -14.0M | -15.6M | -13.0M | -10.9M |
| Interest expense | 562.4K | 84.1K | 322.8K | 1.10M | 0 | 298 | 454 | |||
| Income before tax | -12.0M | -11.0M | -8.57M | -14.1M | -10.1M | -13.9M | -12.9M | -14.7M | -12.9M | -10.9M |
| Income tax | 5.99K | 5.54K | 3.05K | 2.82K | 2.57K | -1.65K | 12.7K | 5.28K | -1.74M | 3.75K |
| Net income | -12.0M | -11.0M | -8.57M | -14.1M | -10.1M | -13.9M | -12.9M | -14.7M | -11.2M | -10.9M |
| Earnings per share, basic | -0.24 | -0.23 | -0.17 | -0.29 | -0.21 | -0.31 | -0.30 | -0.36 | -0.32 | -0.33 |
| Earnings per share, diluted | -0.24 | -0.23 | -0.17 | -0.29 | -0.21 | -0.31 | -0.30 | -0.36 | -0.32 | -0.33 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 30.8M | 40.4M | 51.0M | 18.5M | 71.4M | 60.0M | 63.8M | 62.3M | 28.0M | 24.1M |
| Short-term investments | 0 | 40.0M | 0 | 0 | 0 | |||||
| Receivables | 0 | 0 | ||||||||
| Inventory | 0 | 0 | ||||||||
| Current assets | 31.0M | 41.1M | 51.2M | 59.0M | 72.0M | 60.7M | 64.3M | 62.8M | 28.3M | 24.7M |
| Property, plant and equipment | 8.34K | 25.5K | 45.8K | 45.3K | 57.6K | 55.7K | 40.5K | 53.1K | 62.9K | 90.7K |
| Goodwill | 9.60M | 9.60M | 9.60M | 9.60M | 9.60M | 9.60M | 9.60M | 9.60M | 9.60M | 9.60M |
| Total assets | 45.6M | 55.9M | 66.3M | 74.2M | 87.4M | 75.4M | 79.2M | 77.2M | 43.4M | 39.8M |
| Accounts payable | 625.0K | 1.10M | 1.00M | 424.6K | 402.7K | 616.6K | 451.3K | 616.8K | 1.52M | 367.3K |
| Current liabilities | 3.80M | 2.96M | 3.28M | 3.19M | 2.83M | 2.19M | 2.23M | 2.19M | 2.88M | 1.63M |
| Long-term debt | 0 | 0 | ||||||||
| Total debt | 194.3K | 193.8K | 215.9K | 681.1K | 826.6K | 184.8K | 399.3K | 27.2M | 967.0K | |
| Total liabilities | 4.02M | 3.37M | 3.89M | 3.91M | 3.73M | 4.09M | 4.31M | 4.12M | 4.78M | 5.28M |
| Shareholders' equity | 41.6M | 52.5M | 62.4M | 70.2M | 83.7M | 71.3M | 74.9M | 73.1M | 38.6M | 34.5M |
| Shares outstanding | 49.2M | 49.0M | 49.0M | 49.0M | 49.0M | 45.0M | 43.9M | 42.1M | 36.5M | 34.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -9.81M | -10.6M | -7.43M | -12.9M | -9.38M | -10.8M | -9.12M | -9.11M | -6.92M | -6.55M |
| Capital spending | -2.90K | -895 | -21.3K | -5.01K | -28.7K | -36.5K | -11.3K | -10.2K | -10.2K | -84.5K |
| Free cash flow | -9.81M | -10.6M | -7.45M | -12.9M | -9.41M | -10.9M | -9.14M | -9.12M | -6.92M | -6.63M |
| Cash from investing | -2.90K | -697 | 39.9M | -40.0M | -28.7K | -36.5K | -11.3K | 626.3K | -84.5M | -84.5K |
| Cash from financing | 244.0K | 0 | 32.5B | 7.92K | 20.8M | 7.11M | 10.6M | 42.8M | 10.8M | 8.67M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | -112.3K | -192.1K | 27.3K | 51.0K | 77.3K | 87.7K | ||||
| Change in cash | -9.55M | -10.6M | 32.5M | -52.9M | 11.4M | -3.76M | 1.48M | 34.3M | 3.87M | 2.04M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 16, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| SCHEDULE 13G · Big-stake notice | Oct 30, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 29, 2026 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 29, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Sep 28, 2026 | Material contract | SEC |
| 8-K · Current report | Sep 2, 2026 | Current report | SEC |
| 8-K · Current report | Aug 19, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 25, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| PRER14A | Apr 20, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| 10-K · Annual report | Mar 10, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 20, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 424B5 · Prospectus | Dec 30, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 30, 2025 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | Dec 12, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Dec 9, 2025 | Other filings | SEC |
| S-3 · Registration statement | Dec 5, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| EFFECT · Notice that a registration is effective | Oct 1, 2025 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 26, 2025 | Other filings | SEC |
| S-1 · Registration statement | Aug 22, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2025 | Material contract | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 18, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Mar 11, 2025 | Current report | SEC |
| 10-K · Annual report | Feb 19, 2025 | Annual report | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2024 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Apr 26, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2024 | Meeting notice | SEC |
| 8-K · Current report | Apr 1, 2024 | Management or board change | SEC |
| 10-K · Annual report | Feb 15, 2024 | Annual report | SEC |
| S-8 POS | Jan 19, 2024 | Offer document | SEC |
| S-8 POS | Jan 19, 2024 | Offer document | SEC |
| S-8 POS | Jan 19, 2024 | Offer document | SEC |
| S-8 POS | Jan 19, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 11, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 8, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 8, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 7, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 22, 2023 | Current report | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 11, 2023 | Quarterly report | SEC |
| 8-K · Current report | Apr 26, 2023 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 26, 2023 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2023 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2023 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Mar 28, 2023 | Annual report | SEC |
| 10-K · Annual report | Feb 16, 2023 | Annual report | SEC |
| 4 · Change in ownership | Jan 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 25, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 23, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 10, 2022 | Quarterly report | SEC |
| 424B5 · Prospectus | Sep 30, 2022 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Sep 7, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 1, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 31, 2022 | Other filings | SEC |
| S-3 · Registration statement | Aug 26, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 11, 2022 | Quarterly report | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 12, 2022 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jun 27, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 21, 2022 | Management or board change | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 15, 2022 | Meeting outcome | SEC |
| S-8 · Registration statement for employee plans | May 13, 2022 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2022 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 26, 2022 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2022 | Meeting notice | SEC |
| 8-K · Current report | Apr 4, 2022 | Current report | SEC |
| 10-K · Annual report | Feb 16, 2022 | Annual report | SEC |
| 4 · Change in ownership | Jan 31, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Jan 31, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 12, 2021 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 25, 2021 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 12, 2021 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Aug 10, 2021 | Insider trade | SEC |
| 8-K · Current report | Aug 2, 2021 | Management or board change | SEC |
| 4 · Change in ownership | Jul 23, 2021 | Insider trade | SEC |
| 8-K · Current report | Jul 23, 2021 | Material contract | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 12, 2021 | Big-stake notice | SEC |
| 4 · Change in ownership | Jun 28, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Jun 21, 2021 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2021 | Meeting outcome | SEC |
| 4 · Change in ownership | May 20, 2021 | Insider trade | SEC |
| 8-K · Current report | May 18, 2021 | Current report | SEC |
| 10-Q · Quarterly report | May 13, 2021 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2021 | Current report | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2021 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2021 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 26, 2021 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 26, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 15, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2021 | Insider trade | SEC |
| 10-K · Annual report | Feb 18, 2021 | Annual report | SEC |
| 424B3 · Prospectus | Feb 12, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Feb 11, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 8, 2021 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 5, 2021 | Other filings | SEC |
| 4 · Change in ownership | Feb 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2021 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2021 | Insider trade | SEC |
| 8-K · Current report | Feb 1, 2021 | Financing | SEC |
| S-3 · Registration statement | Jan 29, 2021 | Offer document | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 29, 2021 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 21, 2021 | Insider trade | SEC |
| SC 13D · Big-stake notice | Jan 21, 2021 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2021 | Material contract | SEC |
| 10-Q · Quarterly report | Oct 26, 2020 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 22, 2020 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 22, 2020 | Insider trade | SEC |
| 8-K · Current report | Oct 21, 2020 | Management or board change | SEC |
| 4 · Change in ownership | Sep 16, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Aug 7, 2020 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 28, 2020 | Quarterly report | SEC |
| 3 · Initial statement of ownership | Jun 24, 2020 | Insider trade | SEC |
| 8-K · Current report | Jun 19, 2020 | Management or board change | SEC |
| 4 · Change in ownership | Jun 17, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2020 | Insider trade | SEC |
| 8-K · Current report | Jun 17, 2020 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 15, 2020 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2020 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2020 | Meeting notice | SEC |
| 10-Q · Quarterly report | Apr 23, 2020 | Quarterly report | SEC |
| 8-K · Current report | Apr 23, 2020 | Management or board change | SEC |
| 8-K · Current report | Apr 15, 2020 | Management or board change | SEC |
| 4 · Change in ownership | Apr 13, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Apr 13, 2020 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Mar 16, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Mar 12, 2020 | Insider trade | SEC |
| 10-K · Annual report | Feb 13, 2020 | Annual report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 5, 2020 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 10, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2020 | Insider trade | SEC |
| 4 · Change in ownership | Jan 10, 2020 | Insider trade | SEC |
| 8-K · Current report | Oct 28, 2019 | Current report | SEC |
| 8-K · Current report | Oct 25, 2019 | Current report | SEC |
| 10-Q · Quarterly report | Oct 24, 2019 | Quarterly report | SEC |
| 8-K · Current report | Aug 23, 2019 | Material contract | SEC |
| 424B5 · Prospectus | Aug 23, 2019 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Aug 23, 2019 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 20, 2019 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 14, 2019 | Other filings | SEC |
| S-3 · Registration statement | Aug 9, 2019 | Offer document | SEC |
| 8-K · Current report | Jul 26, 2019 | Current report | SEC |
| 10-Q · Quarterly report | Jul 25, 2019 | Quarterly report | SEC |
| 8-K · Current report | Jul 25, 2019 | Management or board change | SEC |
| S-8 · Registration statement for employee plans | Jun 21, 2019 | Offer document | SEC |
| 4 · Change in ownership | Jun 13, 2019 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2019 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 11, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2019 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2019 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2019 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 1, 2019 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 26, 2019 | Meeting notice | SEC |
This page holds 200 of 881 filings. Open Filings
Cap table
Built by 6ix from MediciNova, Inc.’s releases · as of Nov 10, 2026
- Common shares
- 51,232,668
- Fully diluted
- 51,232,668
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 51,232,668 | Nov 10, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 10, 2026 | 51,232,668 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jeff Himawan Other companies: Gyre Therapeutics, Inc. (Director · Aug 20, 2015 – Aug 20, 2015 · Past); Horizon Pharma PLC (Director · Jul 28, 2011 – May 3, 2018 · Past); Iomai Corp (Director · Jan 25, 2006 – Oct 25, 2006 · Past) | Director · Jan 9, 2006 – Jun 14, 2011 · Past |
| Nicole Lemerond Other companies: GeoVax Labs, Inc. (Director · Since at least Aug 31, 2022); InMed Pharmaceuticals Inc. (Director · Since at least Aug 8, 2022) | Director · Since at least Aug 4, 2023 |
| Ryan Selhorn Other companies: Aytu BioPharma, Inc. (Chief Financial Officer · Since at least Nov 11, 2024) | Chief Financial Officer · Mar 31, 2016 – Mar 31, 2016 · Past |
| David H. Crean | Ph.D.Chief Business OfficerMediciNova · Oct 6, 2026 – Nov 5, 2026 · Past |
| Edward C Stepanow Jr | Chief Financial Officer · Jun 19, 2020 – Jun 19, 2020 · Past |
| Geoffrey OBrien | Vice President · Oct 15, 2013 – Jan 9, 2024 · Past |
| Hideki Nagao | Director · Since at least Jan 4, 2006 |
| Kazuko Matsuda | Member of the Board of Directors, Senior Vice President, Chief Medical Officer, Representative, Tokyo Office · Since at least Jan 9, 2024 |
| Kirk William Johnson | Chief Scientific Officer · Jun 14, 2012 – May 13, 2013 · Past |
| Kousuke Nakata | Director · Jan 15, 2014 – Jan 15, 2014 · Past |
All 13 people
| Person | Seat |
|---|---|
| Masatsune Okajima | VP and Head of Japanese Office · Jan 18, 2017 – Feb 28, 2019 · Past |
| Yoshio Ishizaka | Director · Apr 8, 2014 – Jun 10, 2019 · Past |
| Yuichi Iwaki | Executive Chairman of the Board, President and Chief Executive Officer, Founder · Since at least Sep 24, 2026 |
Log in to ask 6ix AI your own questions about MediciNova, Inc.